Clinical trials
for patients

The aim is to evaluate whether PET/CT scanning with [68Ga]Ga-PTF can improve diagnostic accuracy compared to [18F]FDG in patients with MZL, allowing a more accurate determination of the extent of disease.

The purpose of this study is to evaluate the effects, good or bad, of ranibizumab delivered via an ocular implant (also known as a Port Delivery System with ranibizumab or PDS device) in patients with wet AMD. The ocular implant delivers ranibizumab continuously (without interruption) over an extended period of time to the back of the eye and can be recharged by the study doctor. The intention is to keep the implant in the eye permanently, unless it needs to be removed for medical reasons.

The objective is to investigate the safety and tolerability, characterise the DLTs and determine the DMT and/or DMF and/or recommended dose phase II dose (RP2D) of AZD8421 as monotherapy and also in combination with other anticancer drugs.

We conducted this trial to learn more about an experimental drug called ALXN2220 for the treatment of adult patients with transthyretin cardiac amyloidosis, and also to better understand the disease studied and the associated health problems.

The main goal of this study is to find out how well tinengotinib works and how safe tinengotinib is compared to the study doctor's choice of chemotherapy treatment. This study will be divided into 2 parts: Part A and Part B. The purpose of Part A of the study will be to determine the best dose of tinengotinib to use in Part B of the study. The purpose of Part B is to get more information about how tinengotinib works and its safety compared to the study doctor's choice of treatment.

The main objective is to evaluate the safety and tolerability of increasing doses of AMX-500 as monotherapy (Part 1) and in combination with another therapeutic agent (Part 3).

The objective of this clinical trial is to learn about the safety and efficacy (how well a drug works) of the clinical trial drug (HSK3486) compared to propofol in patients undergoing scheduled surgery with general anesthesia using endotracheal intubation (IE).

The objective of the study is to apply the maximum dose of luspatercept allowed by approval at initiation of therapy. Instead of 1.0 mg/kg per treatment, a dose increase to 1.75 mg/kg body weight (higher dose) is intended. This adapted dose is intended to ascertain the following: Can reduced transfusion dependence be achieved by treatment with luspatercept at a higher dose alone? Can the higher dose prolong the transfusion-free period (response) and improve hemoglobin levels in MDS-SA patients? ...

The purposes of the study are to evaluate the efficacy, safety and tolerability of a single dose of atogepant compared to placebo for the acute treatment of a single migraine attack, and to evaluate the efficacy, safety and tolerability of atogepant for the acute treatment of multiple migraine attacks.

GEN1055 is an experimental drug, which means that it has not yet been approved to treat malignant solid tumors. The trial has 2 parts: part 1 (dose escalation) is the beginning of the trial, where they are going to look for the safest dose to continue with, and part 2 (scale-up) is where they scale up the trial and give that dose to many more participants.